ALX Oncology Holdings 株価情報 (NASDAQ: ALXO)

ALX Oncology Holdings (NASDAQ:ALXO) 株価情報

ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

News

FRSX

Foresight Autonomous Holdings Agrees For POC Project With Global Tier One Automotive Supplier To Improve Urban Transit Safety Through Precision Curb Detection System

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $(8.58) by 102.8 percent. This is a 91.27 percent decrease over earnings of $2.75 per share from the same period last year. The company reported quarterly sales of $5.58 million which beat the analyst consensus estimate of $5.50 million by 1.45 percent. This is a 40.55 percent decrease over sales of $9.39 million the same period last year.

Earnings

Earnings Beats

ALUR

Allurion Technologies Q1 Adj. EPS $0.24 Beats $(8.58) Estimate, Sales $5.58M Beat $5.50M Estimate

Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) will release its second-quarter earnings results before the <a href="https://www.benzinga.com/quote/DE/earnings">opening bell on Thursday, May 15.</a>
Analysts expect the Moline, Illinois-based company to report quarterly earnings at $5.64 per share, down from $8.53 per share in the year-ago period. According to data from Benzinga Pro, Deere projects quarterly revenue at $10.79 billion, compared to $13.61 billion a year earlier.
On April 22, Oppenheimer analyst Kristen Owen maintained Deere with an Outperform rating and raised the price target from $510 to $513.
With the recent buzz around Deere, some investors may be eyeing potential gains from the company's dividends. As of now, Deere offers an annual dividend yield of 1.30%. That&#8217;s a quarterly dividend of $1.62 per share ($6.48 a year).  So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $461,676 or around 926 shares. For a more modest $100 per month or $1,200 per year, you would need $92,235 or around 185 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($6.48 in this case). So, $6,000 / $6.48 = 926 ($500 per month), and $1,200 / $6.48 = 185 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
DE Price Action: Shares of Deere, which operates under the brand name John Deere, gained 0.6% to close at $498.57 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Deere Stock Ahead Of Q2 Earnings

NETSOL Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTWK#NASDAQ">NTWK</a>) reported quarterly earnings of $0.12 per share. This is a 300 percent increase over earnings of $0.03 per share from the same period last year. The company reported $17.53 million in sales this quarter. This is a 13.38 percent increase over sales of $15.46 million the same period last year.

NTWK

NETSOL Technologies Q3 EPS $0.12 Up From $0.03 YoY, Sales $17.53M Up From $15.46M YoY

Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>), a leader in enterprise AI-powered cloud data management, today announced a strategic agreement with Microsoft. This milestone extends the long-standing collaboration between the two companies, continuing innovation and customer adoption on the Microsoft Azure cloud platform. The announcements were made at Informatica World, the company's annual data management and AI conference held in Las Vegas.
Informatica and Microsoft are working closely to deliver unified, AI-powered solutions that combine Informatica's Intelligent Data Management Cloud&#x2122; platform with key Microsoft services, including Microsoft Fabric and Microsoft Azure. Informatica's cloud data management platform is available as a SaaS offering on Azure and via Azure Marketplace, enabling customers to build a trusted, secure and innovative data foundation to power their analytics and AI-driven business transformations.

INFA

Informatica Enters Into New Strategic Agreement With Microsoft To Accelerate Customer Adoption, Continuing Innovation And Customer Adoption On The Microsoft Azure Cloud Platform

Newly granted patent is part of the expanding intellectual property portfolio directed to:
-generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and
-incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jPx2ufkMgU0msrd130bt97ODr8ugiUJEn3waONvhWdO81_Tm48fKEVz6J_0WsDT09f-bPr0glnd07_FmMGH1e8p2YsmA3yRAYQrFNs8tWTY=">Surrozen, Inc.</a> ("Surrozen" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278.

SRZN

Surrozen Granted US Patent To Antibody-Based Molecules Targeting Key Receptors In Wnt Pathway

Wells Fargo analyst Stan Berenshteyn upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Equal-Weight to Overweight and raises the price target from $31 to $35.

Upgrades

Price Target

Analyst Ratings

OMCL

Wells Fargo Upgrades Omnicell to Overweight, Raises Price Target to $35

Brag House Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) ("Brag House" or the "Company"), the premier Gen Z engagement platform that operates at the intersection of gaming, college sports, and social interaction, today announced an update on its investigation into recent trading activity in its stock. With assistance from its outside advisors, the Company's investigation has identified preliminary data suggesting the Company may have been the subject of illegal naked short selling. Accordingly, today the Company sent letters to the SEC, FINRA, and Nasdaq regarding these preliminary findings and requested they open an immediate investigation into the suspected trading activity.
Naked short sales take time to verify, but preliminary financial indicators cause the Company to believe that abusive naked short selling may have occurred. Naked short selling is illegal and damages stockholder value in a company by artificially pushing its stock price down. Common indicators of abusive naked short selling include unusually high trading volume, high financing rates to borrow stock, and persistent failures to deliver that culminate in significant downward pressure on a company's stock price.

Short Sellers

Management

Brag House Launches Investigation Into Suspected Illegal Naked Short Selling, Cites Preliminary Evidence Of Abusive Trading Activity And Urges SEC, FINRA, And Nasdaq To Initiate Immediate Probe Into Unusual Volume, Stock Borrowing Rates, And Price Pressure

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tivichealth.com%2F&amp;esheet=54254631&amp;newsitemid=20250514637661&amp;lan=en-US&amp;anchor=Tivic+Health%26%23174%3B+Systems%2C+Inc.&amp;index=1&amp;md5=d4aba0585fc1d150035e1c00a7f0e1c0">Tivic Health&#xAE; Systems, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod&#x2122;, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food &amp; Drug Administration.
Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#OTC">SCPX</a>), which will be the primary U.S. manufacturer for Entolimod&#x2122;. Scorpius plans to utilize its scientific and technical expertise to validate the commercial manufacturing process for Tivic's lead candidate, Entolimod&#x2122;.
The GMP Validation Program is valued at approximately $4.1 million and is inclusive of the following activities: cell line verification, legacy process verification, GMP scale-up production, drug product fill and finish, analytical development and qualification, and finally upstream and downstream optimization of the process. All of these activities are designed to ensure Tivic submits to the FDA a complete CMC (chemistry, manufacturing, and control) package for its Entolimod BLA.

SCPX

TIVC

Tivic Health Advances Entolimod Toward FDA BLA Filing With GMP Manufacturing Validation

Wells Fargo analyst Gabe Hajde downgrades Magnera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) from Overweight to Equal-Weight and lowers the price target from $22 to $16.

Downgrades

MAGN

Wells Fargo Downgrades Magnera to Equal-Weight, Lowers Price Target to $16

CSP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSPI#NASDAQ">CSPI</a>) reported quarterly losses of $(0.01) per share. This is a 106.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported $13.15 million in sales this quarter. This is a 4.08 percent decrease over sales of $13.71 million the same period last year.

CSPI

CSP Q2 EPS $(0.01) Down From $0.16 YoY, Sales $13.15M Down From $13.71M YoY

Biotech

General

ERNA

Ernexa Therapeutics Establishes Texas Subsidiary To Support Ongoing Development Of ERNA-101 And Future Clinical Operations

SAIH

SAIHEAT Receives Invention Patent Authorization Notice For Its 'Control Rod Drive Mechanism for Small Modular Pressurized Water Reactors (SMRs).'

STRR

Star Equity Hldgs Q1 2025 Adj. EPS $(0.52) Misses $(0.25) Estimate, Sales $12.92M Miss $16.35M Estimate

The conversion of a Qatari 747 jet into the&nbsp;new Air Force One for&nbsp;President Donald Trump could&nbsp;cost over $1 billion and&nbsp;take several years, according to aviation experts.
What Happened: Several aviation experts have cautioned that converting a 13-year-old jet owned by Qatar into the new Air Force One could end up costing U.S. taxpayers hundreds of millions of dollars over a period of time. The refurbishment of the commercial plane, currently valued at $400 million, would exceed its present worth, <a href="https://www.nbcnews.com/politics/national-security/turning-qatari-747-air-force-one-cost-1-billion-take-years-experts-say-rcna206582">reported</a> NBC News.
Richard&nbsp;Aboulafia, managing director at&nbsp;AeroDynamic Advisory, stated that the conversion process would be complex and time-consuming. According to Aboulafia, the Qatari jumbo jet would have to be extensively dismantled to eliminate any security risks, then equipped with expensive, advanced systems for secure government communication and defense—potentially pushing the project timeline into the 2030s. 
Hence, it might not be finished before Trump&#8217;s term ends in 2029. The plane is then expected to be transferred to his presidential library foundation.
Aviation experts have questioned the financial and practical sense of the project, given that Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is already working on&nbsp;multi-year project is underway to convert two 747s as replacements for the current Air Force One aircraft. Boeing, the original manufacturer, is expected to secure the contract to refurbish the Qatari 747.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45395189/mark-cuban-takes-a-jab-at-howard-lutnick-in-which-time-share-company-is-he-going-to-get-a-job-in-sales-at" target="_blank" rel="noreferrer noopener">Mark Cuban Takes A Jab At Howard Lutnick, &#8216;In Which Time Share Company Is He Going To Get A Job In Sales At&#8217;</a>
Why It Matters: The proposed conversion of the Qatari jet has been a subject of controversy since President Trump&#8217;s acceptance of the $400 million gift from Qatar&#8217;s royal family. 
Critics, including former Republican presidential contender Nikki Haley and former Treasury Secretary Larry Summers, have <a href="https://www.benzinga.com/news/25/05/45400944/as-nikki-haley-slams-trumps-400-million-boeing-jet-gift-from-qatar-bill-ackman-cites-national-security-implications-only-a-fool-would-not-accept-this-says-president">voiced </a>concerns about the implications for national security and potential corruption. The<a href="https://www.benzinga.com/25/05/45338985/trump-reportedly-set-to-accept-flying-palace-from-qatar-white-house-says-lavish-gift-of-boeing-jumbo-jet-complies-with-all-applicable-laws"> lavish gift </a>was defended by the Trump administration as complying with all applicable laws.
Meanwhile, President Trump defended the gift and clarified on Truth Social that the aircraft was being given to the Department of Defense and not him. He further mentioned that it would be temporarily used as Air Force One until Boeing delivers, while adding that the gift was saving taxpayers money.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45314762/charlie-munger-was-once-asked-why-warren-buffett-was-so-much-richer-and-replied-he-got-an-earlier-start-before-adding-why-was-albert-einstein-poorer-than-i-was" target="_blank" rel="noreferrer noopener">Charlie Munger Was Once Asked Why Warren Buffett Was So Much Richer — He Replied, &#8216;He Got An Earlier Start,&#8217; Then Added, &#8216;Why Was Albert Einstein Poorer Than I Was?&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Tech

Trump's Qatar Jet Gift Could Cost Taxpayers $1 Billion — And He Still May Not Be Able To Use It This Term, Say Experts

DeFi Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) reported quarterly losses of $(0.55) per share. This is a 21.43 percent increase over losses of $(0.70) per share from the same period last year. The company reported $287.17 thousand in sales this quarter. This is a 30.15 percent decrease over sales of $411.14 thousand the same period last year.

DFDV

DeFi Development Q1 EPS $(0.55) Up From $(0.70) YoY, Sales $287.17K Down From $411.14K YoY

BLUE

Carlyle, SK Capital Partners And bluebird bio Amend Merger Agreement; Stockholders May Elect To Receive Either $3/Share Plus CVR Of $6.84/Share In Cash Payable Upon Achievement Of A Net Sales Milestone Or $5/Share With No CVR

Vuzix&#xAE; Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>), ("Vuzix"), a leading supplier of AI-powered smart glasses, waveguides and Augmented Reality (AR) technologies and Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) ("Himax"), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced the joint debut of a next-generation AR optical module at Display Week 2025, one of the premier symposiums and exhibitions in the display industry and taking place May 11–16, 2025 in San Jose, California. The demonstration features Himax's latest ultra-luminous, miniature Dual-Edge Front-lit LCoS microdisplay seamlessly integrated with Vuzix' production-ready waveguides.&nbsp;Together, the technologies form a fully integrated module that delivers breakthrough brightness and power efficiency in an unparalleled compact design, enabling sleek, lightweight AR glasses for both enterprise and consumer applications. This co-design initiative, scheduled for commercial release at the end of 2025, focuses on optimizing optical performance to deliver industry-leading visual quality.

HIMX

VUZI

Vuzix And Himax Technologies Announce Joint Debut Of Next-Gen AR Optical Module At Display Week 2025

William Blair analyst Brian Weinstein downgrades Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) from Outperform to Market Perform.

BDSX

William Blair Downgrades Biodesix to Market Perform

Buybacks

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Announces $50M Share Repurchase Program

Press Releases

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Health Care

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004,  a Novel EGFR-targeted Antibody-drug Conjugate

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

Comments

ALX Oncology Holdings

ニュース

パートナーシップ

ベンジンガ・グローバル